SCHEDULE: Affinity Asset Advisors Reduces Karyopharm Stake to 8.6%

Affinity Asset Advisors, LLC and Michael Cho have reported a reduced beneficial ownership stake of 8.6% in Karyopharm Therapeutics Inc., down from 9.99% previously.

Summary

• Affinity Asset Advisors, LLC and Michael Cho are the reporting persons for this Schedule 13G Amendment No. 1.
• The issuer is Karyopharm Therapeutics Inc., with its common stock, $0.0001 par value per share, as the class of securities.
• As of the filing date (January 29, 2026), the reporting persons beneficially own 1,713,092 shares of Common Stock, representing 8.6% of the class outstanding.
• This amount includes 1,573,517 shares of Common Stock issuable upon the exercise of warrants.
• The warrants are subject to a beneficial ownership limitation of 9.99% of the outstanding shares.
• As of December 31, 2025, the Fund and the Adviser beneficially owned 1,932,373 shares, representing 9.99% of the Common Stock outstanding, which included 1,032,798 shares issuable upon warrant exercise after applying the limitation.
• The reporting persons now hold sole voting and dispositive power over 1,713,092 shares as of the filing date, a change from shared power reported as of December 31, 2025.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a slightly negative signal, as a significant institutional investor has reduced its beneficial ownership percentage from 9.99% to 8.6%, potentially indicating a partial divestment or a less aggressive stance.

Positives

• Affinity Asset Advisors, LLC and Michael Cho maintain a significant beneficial ownership stake of 8.6% in Karyopharm Therapeutics Inc., indicating continued institutional interest.
• The reporting persons now exercise sole voting and dispositive power over their 1,713,092 shares, a shift from shared power previously.

Negatives

• The beneficial ownership percentage has decreased from 9.99% as of December 31, 2025, to 8.6% as of the filing date (January 29, 2026), implying a reduction in the overall stake.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that a reduction in a significant institutional stake, even if still substantial, can sometimes be interpreted by the market as a slight decrease in confidence or a portfolio rebalancing within the biotechnology or pharmaceutical sector. This type of filing indicates a passive investment rather than an activist stance.

Stakeholder Impact

• Shareholders: A reduction in a significant institutional stake could be perceived as a decrease in confidence, potentially influencing market sentiment.

Key Dates

Recommendation

The filing indicates a reduction in beneficial ownership from 9.99% to 8.6% by Affinity Asset Advisors, LLC and Michael Cho. While this is a notable decrease in institutional stake, the filing does not provide the underlying reasons for this change (e.g., portfolio rebalancing, change in outlook). The remaining 8.6% is still a significant position. Without further information on Karyopharm Therapeutics Inc.'s operational performance or strategic direction, a 'hold' recommendation is prudent, acknowledging the reduced institutional confidence while not signaling a complete loss of faith.

Keywords

Karyopharm Therapeutics, Affinity Asset Advisors, Michael Cho, Schedule 13G, beneficial ownership, common stock, warrants, institutional ownership